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Abstract
Introduction: Acute leukemias very rarely present with jaundice. Herein we report a case of precursor B-cell acute
lymphoblastic leukemia that presented with jaundice in an adult.
Case presentation: A 44-year-old Hispanic man presented with right upper quadrant abdominal pain and
jaundice. His initial blood work revealed pancytopenia and hyperbilirubinemia. Direct bilirubin was more than 50%
of the total. His imaging studies were unremarkable except for hepatomegaly. All blood screening tests for various
hepatocellular etiologies were normal. A diagnosis of precursor B-cell acute lymphoblastic leukemia was made
upon liver biopsy. It also showed lymphocytic infiltration of the hepatic parenchyma leading to bile stasis. The
diagnosis was subsequently confirmed upon bone marrow biopsy. The patient was treated with a
hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone regimen.
Conclusion: Acute lymphoblastic leukemia should be one of the differential diagnoses that should be considered
when initial work-up for jaundice is inconclusive. Some cases of acute lymphoblastic leukemia have been reported
in both adults and children to have presented with the initial manifestation of jaundice, but only a few had no
radiographic evidence of biliary obstruction. Such presentation can pose a serious diagnostic dilemma for clinicians.
This manuscript attempts to highlight it. Moreover, we believe that if acute lymphoblastic leukemia presentations
similar to this case continue to be reported in adults or children, a specific immunophenotypic expression and
cytogenetic abnormality may be found to be associated with hepatic infiltration by leukemia. This may substantially
contribute to the further understanding of the pathophysiology of this hematologic disease.
Introduction
Acute lymphoblastic leukemia (ALL) is a clonal hemato-
logic disorder. It involves excessive proliferation and
impaired differentiation of leukemic blasts that lead to
inadequate normal hematopoiesis. Thus patients usually
present with symptoms resulting from bone marrow
failure. The extra-medullary form of this disease is rarely
reported. However, when found, it most commonly
involves the bones, followed by soft tissue, skin and
lymph nodes. It is extremely rare for patients with ALL
to present with hepatic manifestations. Herein we pre-
sent a case of precursor B-cell (pre-B-cell) ALL that
manifested as obstructive jaundice. The case elaborates
this unique presentation and that infiltrative involve-
ment of leukemia should be considered when the initial
work-up for obstructive jaundice is inconclusive. More-
over, it highlights the challenges in planning chemother-
apeutic treatment in the presence of an already
compromised hepatic function.
Case presentation
A 44-year-old Hispanic man presented to our hospital
with the chief complaints of pain in the right upper
quadrant of the abdomen and jaundice. These symp-
toms were associated with intermittent nausea and
vomiting, generalized weakness, poor appetite, clay-
colored stools and mild, generalized itching. The
patient’s symptoms had developed gradually and had
worsened over the course of a few weeks. He denied a
history of fever or chills or a change in bowel habits. He
did report weight loss of about 20 pounds during the six
months prior to presentation. It was not entirely unin-
tentional, however, as he was attempting to lose some
weight. This symptom was not associated with night
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was unremarkable.
His medical history included diabetes mellitus and
hypertension. His social history was significant for
smoking. He had quit alcohol intake five months before
his presentation to our hospital. He denied any intrave-
nous drug use, recent travel history or exposure to any
people who were ill. He did not report any recent
change in his medications and was tolerating his aspirin,
sitagliptin, fosinopril, metformin and repaglinide without
reported side effects. His physical examination was sig-
nificant for pallor, icteric sclerae and non-tender hepato-
megaly. His vital signs were normal. His body
temperature was 98°F, his blood pressure was 125/78
mmHg, his pulse was 76 beats/minute and his respira-
tory rate was 16 breaths/minute. The patient was
admitted to the medical service for further work-up.
A complete blood count was significant for pancytope-
nia, with hemoglobin 8.9 g/dL, white blood cell count
3600/mm
3 and platelet count 94,000/mm
3. His chemis-
try panel revealed hyperbilirubinemia, with total biliru-
bin 10 mg/dL, direct bilirubin 7 mg/dL and only
minimal elevation of transaminases (alanine transami-
nase 74I U/L and aspartate transaminase 52I U/L). His
alkaline phosphatase and g-glutamyl transferase levels
w e r es i g n i f i c a n t l yr a i s e da t2 9 3 IU / La n d3 2 7 IU / L ,
respectively. This profile is most consistent with
obstructive jaundice. However, to rule out hepatocellular
causes in this patient, we requested screens for hepatitis
A immunoglobulin M (IgM) antibody, hepatitis B sur-
face antigen, anti-nuclear antibodies, anti-smooth mus-
cle antibodies, anti-mitochondrial antibodies, peri-
nuclear anti-neutrophil cytoplasmic antibodies and
human immunodeficiency virus 1/2 antibodies, and all
serologies came back negative. The patient’ss e r u m
levels of a-fetoprotein and CA 19-9 were also found to
be within normal limits. His coagulation profile and
electrolytes were normal.
About two weeks prior to presentation this patient
had undergone magnetic resonance cholangiopancreati-
cography at another hospital. The scans did not show
any intra-or extra-hepatic biliary duct dilatation. Mag-
netic resonance imaging of the liver with intravenous
contrast enhancement done at our hospital revealed
hepatomegaly. A right upper quadrant sonogram con-
firmed the presence of hepatomegaly with increased par-
enchymal echogenicity, suggestive of fatty infiltration or
hepatocellular disease. These imaging studies did not
show any evidence of intra-or extra-hepatic biliary duct
dilatation and thus failed to fully explain the obstructive
jaundice with a bilirubin level of 10 mg/dL (Figure 1).
The patient’s pancytopenia was also further explored
and was best attributed to the possibility of hypoproli-
ferative marrow, as his reticulocyte production index
came back low (0.83), his direct Coombs test was nega-
tive and his haptoglobin level was normal (262 mg/dL).
However, interestingly, his lactate dehydrogenase level
was raised (319I U/L).
As his initial blood work and radiological investiga-
tions were inconclusive, an ultrasound-guided core liver
biopsy was performed. The histopathology revealed lym-
phocytes infiltrating the hepatic parenchyma. His immu-
nohistochemistry (IHC) was positive for CD45, CD10,
terminal deoxynucleotidyl transferase (TdT), CD79A
and PAX5 in the large cell infiltrate. CD20, CD3 and
CD5 were negative in the infiltrate but were found to be
positive in the rare small lymphocytes. Bcl2 was also
faintly positive. CD117, CD23, pan-melanoma marker
and pan-cytokeratin were all negative. The myeloid cell
markers CD13, CD15 and myeloperoxidase were also
negative. This IHC staining pattern was most compati-
ble with a diagnosis of pre-B-cell ALL. Besides this evi-
dence, his hepatic parenchyma showed changes
consistent with bile stasis. The patient’s liver biopsy was
thus suggestive of obstructive jaundice secondary to
infiltration of liver parenchyma with leukemic cells.
This work-up was followed by a bone marrow biopsy,
which confirmed the diagnosis of pre-B-cell ALL. It
showed > 90% cellularity with a diffuse, uniform infiltra-
tion of lymphoid blasts that had prominent nucleoli.
Normal cell lines (erythroid, myeloid and megakaryocy-
tic) were markedly decreased. IHC staining was positive
for CD34, CD10 and TdT. Rare small lymphocytes were
positive for CD3, CD5 and CD20. His IHC was negative
for CD117, CD23, cyclin D1 and myeloperoxidase. Flow
cytometric immunophenotypic analysis of his bone mar-
row aspirate revealed 62% lymphoblasts in the bone
marrow, with the following phenotypes: CD34-positive,
TdT-positive, CD19-positive, CD79a-positive, CD10-
Figure 1 Magnetic resonance imaging scan of the liver with
contrast enhancement obtained during the first week of
admission showing a normal hepatobiliary tree.
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CD20-negative, and cytoplasmic IgM was not expressed.
Dim to moderate positivity of CD13 was identified.
CD33 was negative. Cytogenetic studies showed an addi-
tional copy of chromosomes X and 8 in 7 of 20 mitotic
cells. BCR/ABL rearrangement was not found. Cere-
brospinal fluid cytology and flow cytometry did not
reveal any evidence of leptomeningeal involvement (Fig-
ures 2 and 3).
We planned to initiate a hyper-CVAD protocol
(hyperfractionated cyclophosphamide/vincristine/doxor-
ubicin/dexamethasone) as an induction therapy. As the
patient’ss e r u mb i l i r u b i nl e v e lh a de l e v a t e du pt oav e r y
high level of 13 mg/dL by that time, it was decided to
administer corticosteroids prior to chemotherapy. Pre-
dnisone 100 mg every 12 hours was administered for
five days before hyper-CVAD therapy was initiated. Day
four chemotherapy had to be omitted because of the
patient’s bilirubin level of 11 mg/dL. By day 11, his bilir-
ubin had dropped to 4 mg/dL, and vincristine was admi-
nistered with a 50% dose reduction. The day four
doxorubicin that had been omitted was also adminis-
tered with a 50% dose reduction on day 11. As central
nervous system prophylaxis, intra-thecal methotrexate
was administered on the same day. His bilirubin level
continued to fall gradually. It had completely normalized
by the time cycle 2 of hyper-CVAD therapy was begun.
The patient tolerated the chemotherapy fairly well,
except that he required intermittent packed red blood
cells and platelet transfusions to support his cell counts
and granulocyte colony-stimulating factor and prophy-
lactic intravenous antibiotics for neutropenia. He was
discharged after the recovery of his cell counts with
instructions to follow up with the hematology/oncology
department as an out-patient.
Discussion
Liver involvement by hematologic malignancies is not
infrequent, though it is rarely the initial presentation.
Histopathological examinations of the liver specimens in
an autopsy series revealed that 44% of untreated patients
with leukemias and lymphomas and 26% of the speci-
mens from patients who received chemotherapy either
alone or in combination with radiotherapy had evidence
of neoplastic involvement [1].
Several patterns of hepatic involvement in hematologic
malignancies have been described in the literature. It var-
ies from an asymptomatic hepatic lesion or hepatomegaly
to liver failure. Four cases of fulminant hepatic failure
were reported by Zafrani et al.[ 2 ] .T h e s ep a t i e n t sh a d
moderate to severe infiltration of the liver parenchyma
by leukemic cells with or without accompanying hepatic
necrosis. Rarely, obstructive jaundice is the initial presen-
tation. Lee et al. [3] described a case of AML with granu-
locytic sarcoma obstructing the biliary tract.
Granulocytic sarcoma represents masses of granulocytic
cells. The presence of myeloperoxidase in these myeloid
cells gives these masses a greenish coloration and there-
fore they were historically termed as chloromas [4].
Obstructive jaundice is a very rare presentation of
ALLs. Some cases of T-cell ALL [5] and B-cell ALL
[6,7] have been reported to have presented in associa-
tion with jaundice. Only a few of these cases had no
evidence of biliary obstruction on imaging. The patho-
physiology of jaundice in these cases of ALL was leu-
kemic infiltration of hepatic sinusoids. This is similar
to the pathophysiology of jaundice in our case and is
in contrast to how AML has been reported to cause
Figure 2 Ultrasound-guided core biopsy of the liver showing
small to medium-sized lymphoblasts infiltrating the hepatic
parenchyma.
Figure 3 Bone marrow biopsy showing lymphoblastic
infiltration.
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above.
Hepatic insufficiency at presentation of malignancies
may pose an important therapeutic challenge as it may
reduce tolerance to intensified chemotherapy. Biliary
drainage procedures may prove helpful prior to adminis-
tering chemotherapy in patients with biliary obstruction
but may not be possible in patients with diffuse infiltra-
tion of hepatic parenchyma by leukemic blast cells [8].
Some authors have suggested a short course of predni-
sone prior to instituting full dose chemotherapy [9].
Once a downward trend in bilirubin level is established,
one can proceed with further chemotherapy [10]. We
followed a similar plan for our patient. In our patient,
pre-treatment with prednisone resulted in reduction of
the bilirubin after which hyper-CVAD was administered.
We continue to follow this patient and plan to publish
more about his disease in the event it takes an unusual
course.
Conclusion
In this description of an unusual presentation of ALL in
our patient, we have attempted to emphasize that hema-
tologic malignancies, especially ALL, should be consid-
ered in the differential diagnosis of jaundice. Moreover,
we believe it would be interesting to study the disease
characteristics of ALL in this specific subset of patients
if similar cases continue to be reported. Identification of
a pattern of specific cytogenetic abnormalities and
immunophenotypic expression associated with such
cases may help clinicians to understand the pathogenesis
of the disease’s progression in general and that of liver
involvement in particular. This is why detailed results of
IHC and flow cytometry for our patient are being pub-
lished here.
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